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Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) are the two most common non-Hodgkin
lymphomas (NHLs). Here we sequenced tumour and matched normal DNA from 13 DLBCL cases and one FL case to
identify genes with mutations in B-cell NHL. We analysed RNA-seq data from these and another 113 NHLs to identify
genes with candidate mutations, and then re-sequenced tumour andmatched normal DNA from these cases to confirm
109 genes with multiple somatic mutations. Genes with roles in histone modification were frequent targets of somatic
mutation. For example, 32% of DLBCL and 89% of FL cases had somatic mutations in MLL2, which encodes a histone
methyltransferase, and 11.4% and 13.4% of DLBCL and FL cases, respectively, had mutations in MEF2B, a
calcium-regulated gene that cooperates with CREBBP and EP300 in acetylating histones. Our analysis suggests a
previously unappreciated disruption of chromatin biology in lymphomagenesis.
Non-Hodgkin lymphomas (NHLs) are cancers of B, T or natural
killer lymphocytes. The two most common types of NHL, follicular
lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL),
together comprise 60% of new B-cell NHL diagnoses each year in
North America1. FL is an indolent and typically incurable disease
characterized by clinical and genetic heterogeneity. DLBCL is aggres-
sive and likewise heterogeneous, comprising at least two distinct sub-
types that respond differently to standard treatments. Both FL and the
germinal centre B-cell (GCB) cell of origin (COO) subtype of DLBCL
derive from germinal centre B cells, whereas the activated B-cell
(ABC) variety, which has a more aggressive clinical course, is thought
to originate from B cells that have exited, or are poised to exit, the
germinal centre2. Current knowledge of the specific genetic events
leading to DLBCL and FL is limited to the presence of a few recurrent
genetic abnormalities2. For example, 85–90% of FL and 30–40% of
GCB DLBCL cases3,4 harbour t(14;18)(q32;q21), which results in
deregulated expression of the BCL2 oncoprotein. Other genetic
abnormalities unique to GCB DLBCL include amplification of the
c-REL gene and of the miR-17-92 microRNA cluster5. In contrast to
GCB cases, 24% of ABC DLBCLs harbour structural alterations or
inactivating mutations affecting PRDM1, which is involved in differ-
entiation of GCB cells into antibody-secreting plasma cells6. ABC-
specific mutations also affect genes regulating NF-kB signalling7,8,9,
with TNFAIP3 (also known as A20) and MYD88 (ref. 10) the most
abundantly mutated in 24% and 39% of cases, respectively. To
enhance our understanding of the genetic architecture of B-cell
NHL, we undertook a study to (1) identify somatic mutations and
(2) determine the prevalence, expression and focal recurrence of
mutations in FL and DLBCL. Using strategies and techniques applied
to cancer genome and transcriptome characterization by ourselves
and others11,12,13, we sequenced tumour DNA and/or RNA from 117
tumour samples and 10 cell lines (Supplementary Tables 1 and 2) and
identified 651 genes (Supplementary Figure 1) with evidence of
somatic mutation in B-cell NHL. After validation, we showed that
109 genes were somatically mutated in two or more NHL cases. We
further characterized the frequency and nature of mutations within
MLL2 and MEF2B, which were among the most frequently mutated
genes with no previously known role in lymphoma.
Identification of recurrently mutated genes
We sequenced the genomes or exomes of 14 NHL cases, all with
matched constitutional DNA sequenced to comparable depths
(Supplementary Tables 1 and 2). After screening for single nucleotide
variants followed by subtraction of known polymorphisms and visual
inspection of the sequence read alignments, we identified 717 non-
synonymous variants (coding single nucleotide variants; cSNVs)
affecting 651 genes (Supplementary Figure 1 and Supplementary
Methods). We identified between 20 and 135 cSNVs in each of these
genomes. Only 25 of the 651 genes with cSNVs were represented in
the cancer gene census (December 2010 release)14.
We performed RNA sequencing (RNA-seq) on these 14 NHL cases
and an expanded set of 113 samples comprising 83 DLBCL, 12 FL and
8 B-cell NHL cases with other histologies and 10 DLBCL-derived cell
lines (Supplementary Table 2). We analysed these data to identify
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novel fusion transcripts (Supplementary Table 3) and cSNVs (Fig. 1).
We identified 240 genes with at least one cSNV in a genome/exome or
an RNA-seq ‘mutation hot spot’ (see later), and with cSNVs in at least
three cases in total (Supplementary Table 4).We selected cSNVs from
each of these 240 genes for re-sequencing to confirm their somatic
status. We did not re-sequence genes with previously documented
mutations in lymphoma (for example, CD79B, BCL2). We confirmed
the somatic status of 543 cSNVs in 317 genes, with 109 genes having at
least two confirmed somatic mutations (Supplementary Tables 4 and
5). Of the successfully re-sequenced cSNVs predicted from the gen-
omes, 171 (94.5%) were confirmed somatic, 7 were false calls and 3
were present in the germ line. These 109 recurrently mutated genes
were significantly enriched for genes implicated in lymphocyte activa-
tion (P5 8.33 1024; for example, STAT6, BCL10), lymphocyte dif-
ferentiation (P5 3.53 1023; for example, CARD11), and regulation
of apoptosis (P5 1.93 1023; for example, BTG1, BTG2). Also sig-
nificantly enriched were genes linked to transcriptional regulation
(P5 5.43 1024; for example, TP53) and genes involved in methyla-
tion (P5 2.23 1024) and acetylation (P5 1.23 1022), including
histone methyltransferase (HMT) and acetyltransferase (HAT)
enzymes known previously to be mutated in lymphoma (for example,
EZH2 (ref. 13) and CREBBP (ref. 15); Supplementary Methods).
Mutation hot spots can result frommutations at sites under strong
selective pressure and we have previously identified such sites using
RNA-seq data13.We searched our RNA-seq data for genes withmuta-
tion hot spots, and identified 10 genes that were not mutated in the 14
genomes (PIM1, FOXO1, CCND3, TP53, IRF4, BTG2, CD79B,
BCL7A, IKZF3 and B2M), of which five (FOXO1, CCND3, BTG2,
IKZF3 and B2M) were not previously known targets of point muta-
tion in NHL (Supplementary Table 6 and Supplementary Methods).
FOXO1, BCL7A and B2M had hot spots affecting their start codons.
The effect of a FOXO1 start codon mutation, which was observed in
three cases, was further studied using a cell line in which the initiating
ATG was mutated to TTG. Western blots probed with a FOXO1
antibody revealed a band with a reduced molecular weight, indicative
of a FOXO1 amino-terminal truncation (Supplementary Figure 2),
consistent with use of the next in-frame ATG for translation ini-
tiation. A second hot spot in FOXO1 at T24 was mutated in two cases.
T24 is reportedly phosphorylated by AKT subsequent to B-cell recep-
tor (BCR) stimulation16 inducing FOXO1 nuclear export.
We analysed the RNA-seq data to determine whether any of the
somatic mutations in the 109 recurrently mutated genes showed evid-
ence for allelic imbalance with expression favouring one allele. Out of
380 expressed heterozygous mutant alleles, we observed preferential
expression of the mutation for 16.8% (64/380) and preferential
expression of the wild type for 27.8% (106/380; Supplementary
Table 7). Seven genes showed evidence for significant preferential
expression of the mutant allele in at least two cases: BCL2, CARD11,
CD79B, EZH2, IRF4, MEF2B and TP53; Supplementary Methods. In
27 out of 43 cases with BCL2 cSNVs, expression favoured the mutant
allele, consistent with the previously-described hypothesis that the
translocated (and hence, transcriptionally deregulated) allele of
BCL2 is targeted by somatic hypermutation17. Examples of mutations
at known oncogenic hot spot sites such as F123I in CARD11 (ref. 18)
showed allelic imbalance favouring the mutant allele in some cases.
Similarly, we noted expression favouring two novel hot spot muta-
tions inMEF2B (Y69 and D83) and two sites in EZH2 not previously
reported as mutated in lymphoma (A682G and A692V).
We sought to distinguish new cancer-related mutations from
passenger mutations using the approach proposed previously19. We
reasoned that this would reveal genes with strong selection signatures,
and mutations in such genes would be good candidate cancer drivers.
We identified 26 genes with significant evidence for positive selection
(false discovery rate5 0.03, Supplementary Methods), with either
selective pressure for acquiring non-synonymous point mutations or
truncating/nonsensemutations (SupplementaryMethods; Table 1 and
Supplementary Table 8). Included were known lymphoma oncogenes
(BCL2, CD79B (ref. 9), CARD11 (ref. 18),MYD88 (ref. 10) and EZH2
(ref. 13)), all of which showed signatures indicative of selection for
non-synonymous variants.
Evidence for selection of inactivating changes
We expected tumour suppressor genes to show strong selection for
the acquisition of nonsense mutations. In our analysis, the eight most
significant genes included seven with strong selective pressure for
nonsense mutations, including the known tumour suppressor genes
TP53 and TNFRSF14 (ref. 20 ; Table 1). CREBBP, recently reported as
commonly inactivated in DLBCL15, also showed some evidence for
acquisition of nonsensemutations and cSNVs (Supplementary Figure
3 and Supplementary Table 9). We also observed enrichment for
nonsensemutations in BCL10, a positive regulator of NF-kB, in which
oncogenic truncated products have been described in lymphomas21.
The remaining strongly significant genes (BTG1, GNA13, SGK1 and
MLL2) had no reported role in lymphoma. GNA13 was affected by
mutations in 22 cases includingmultiple nonsensemutations.GNA13
encodes the alpha subunit of a heterotrimeric G-protein coupled
receptor responsible for modulating RhoA activity22. Some of the
mutated residues negatively affect its function23,24, including a
T203A mutation, which also showed allelic imbalance favouring the
mutant allele (Supplementary Table 7). GNA13 protein was reduced
or absent on western blots in cell lines harbouring either a nonsense
mutation, a stop codon deletion, a frame shifting deletion, or changes
affecting splice sites (Supplementary Methods and Supplementary
Figure 4).
HIST1H1C
EZH2
BCL2
MLL2
SGK1
CREBBP
BTG1
GNA13
MEF2B
MYD88
KLHL6
TNFRSF14
IRF8
ETS1
FOXO1
IGH
B2M
CARD11
BTG2
CD70
CD79B
CD58
TP53
TMEM30A
BCL10
FAS
CCND3
STAT3
BCL2
cSNVs
CNV loss
CNV gain
CNV high-level gain
LOH
Figure 1 | Genome-wide visualization of somatic mutation targets in NHL.
Overview of structural rearrangements and copy number variations (CNVs) in
the 11 DLBCL genomes and cSNVs in the 109 recurrently mutated genes
identified in our analysis. Inner arcs represent somatic fusion transcripts
identified in at least one of the 11 genomes. The CNVs and LOH detected in
each of the 11DLBCL tumour/normal pairs are displayed on the concentric sets
of rings. The inner 11 rings show regions of enhanced homozygosity plotted
with blue (interpreted as LOH). The outer 11 rings show somatic CNVs. Purple
circles indicate the position of genes with at least two confirmed somatic
mutationswith circle diameter proportional to the number of cases with cSNVs
detected in that gene. Circles representing the genes with significant evidence
for positive selection are labelled. Coincidence between recurrently mutated
genes and regions of gain/loss are colour-coded in the labels (green, loss; red,
gain). For example B2M, which encodes beta-2-microglobulin, is recurrently
mutated and is deleted in two cases.
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SGK1 encodes a phosphatidylinositol-3-OH kinase (PI(3)K)-
regulated kinase with functions including regulation of FOXO
transcription factors25, regulation of NF-kB by phosphorylating IkB
kinase26, and negative regulation of NOTCH signalling27. SGK1 also
resides within a region of chromosome 6 commonly deleted inDLBCL
(Fig. 1)5. Themechanismbywhich SGK1 andGNA13 inactivationmay
contribute to lymphoma is unclear, but the strong degree of apparent
selection towards their inactivation and their overall high mutation
frequency (eachmutated in 18 of 106DLBCL cases) suggests that their
loss contributes to B-cell NHL. Certain genes are known to bemutated
more commonly in GCB DLBCLs (for example, TP53 (ref. 28) and
EZH2 (ref. 13)). Here, both SGK1 and GNA13 mutations were found
only in GCB cases (P5 1.933 1023 and 2.283 1024, Fisher’s exact
test; n5 15 and 18, respectively) (Fig. 2). Two additional genes
(MEF2B and TNFRSF14) with no previously described role in
DLBCL showed a similar restriction to GCB cases (Fig. 2).
InactivatingMLL2mutations
MLL2 showed the most significant evidence for selection and the
largest number of nonsense SNVs. Our RNA-seq analysis indicated
that 26.0% (33/127) of cases carried at least one MLL2 cSNV. To
address the possibility that variable RNA-seq coverage ofMLL2 failed
to capture some mutations, we PCR-amplified the entireMLL2 locus
(,36 kilobases) in 89 cases (35 primary FLs, 17 DLBCL cell lines, and
37 DLBCLs). Of these cases 58 were among the RNA-seq cohort.
Illumina amplicon re-sequencing (Supplementary Methods) revealed
78 mutations, confirming the RNA-seq mutations in the overlapping
cases and identifying 33 additional mutations. We confirmed the
somatic status of 46 variants using Sanger sequencing (Supplemen-
tary Table 10), and showed that 20 of the 33 additionalmutations were
insertions or deletions (indels). Three SNVs at splice sites were also
detected, aswere10newcSNVs thathadnot beendetected byRNA-seq.
The somatic mutations were distributed acrossMLL2 (Fig. 3a). Of
these, 37% (n5 29/78) were nonsense mutations, 46% (n5 36/78)
were indels that altered the reading frame, 8% (n5 6/78) were point
mutations at splice sites and 9% (n5 7/78) were non-synonymous
amino acid substitutions (Table 2). Four of the somatic splice site
mutations had effects on MLL2 transcript length and structure. For
example, two heterozygous splice site mutations resulted in the use of
a novel splice donor site and an intron retention event.
Approximately half of the NHL cases we sequenced had twoMLL2
mutations (Supplementary Table 10). We used bacterial artificial
Table 1 | Overview of cSNVs and confirmed somatic mutations in most frequently mutated genes
Gene Cases Total Somatic cSNVs
(RNA-seq
cohort)*
P (raw) q NS SP T SP Skew
(M, WT, both){
NS S T NS S T
MLL2{ 16 8 17 17 8 18 10 6.8531028 8.50 31027 0.834 14.4 WT
TNFRSF14 G{ 7 1 7 8 1 7 11 6.8531028 8.50 31027 7.52 118 Both
SGK1 G{ 18 6 6 37 10 6 9 6.8531028 8.50 31027 19.5 61.7 2
BCL10{ 2 0 4 3 0 4 4 6.8531028 8.50 31027 3.62 112 WT
GNA13 G{ 21 1 2 33 1 2 5 6.8531028 8.50 31027 24.1 25.7 Both
TP53 G{ 20 2 1 23 3 1 22 6.8531028 8.50 31027 15.6 14.1 Both
EZH2 G{ 33 0 0 33 0 0 33 6.8531028 8.50 31027 11.4 0.00 Both
BTG2{ 12 6 1 14 6 1 2 6.85 31028 8.50 31027 23.9 35.1 2
BCL2 G{ 42 45 0 96 105 0 43 9.3531028 8.50 31027 3.78 0.00 M
BCL6{1 11 2 0 12 2 0 2 9.3531028 8.50 31027 0.175 0.00 M
CIITA{1 5 3 0 6 3 0 2 9.3531028 8.50 31027 0.086 0.00
FAS{ 2 0 4 3 0 4 2 1.52 31027 1.17 31026 2.54 66.5 WT
BTG1{ 11 6 2 11 7 2 10 1.52 31027 1.17 31026 17.5 52.5 Both
MEF2B G{ 20 2 0 20 2 0 10 2.05 31027 1.47 31026 14.2 0.00 M
IRF8{ 11 5 3 14 5 3 3 4.55 31027 3.03 31026 8.82 28.2 WT
TMEM30A{ 1 0 4 1 0 4 4 6.06 31027 3.79 31026 0.785 65.0 WT
CD58{ 2 0 3 2 0 3 2 2.42 31026 1.43 31025 2.29 69.2 2
KLHL6{ 10 2 2 12 2 2 4 1.00 31025 5.26 31025 5.42 16.4 2
MYD88 A{ 13 2 0 14 2 0 9 1.00 31025 5.26 31025 12.4 0.00 WT
CD70{ 5 0 1 5 0 2 3 1.70 31025 8.48 31025 7.08 44.0 2
CD79B A{ 7 2 1 9 2 1 5 2.00 31025 9.52 31025 10.9 18.3 M
CCND3{ 7 1 2 7 1 2 6 2.80 31025 1.27 31024 6.55 36.3 WT
CREBBP{ 20 7 4 24 7 4 9 1.00 31024 4.35 31024 2.72 6.04 Both
HIST1H1C{ 9 0 0 10 0 0 6 1.80 31024 7.50 31024 11.9 0.00 Both
B2M{ 7 0 0 7 0 0 4 3.90 31024 1.56 31023 16.6 0.00 WT
ETS1{ 10 1 0 10 1 0 4 4.10 31024 1.58 31023 5.76 0.00 WT
CARD11{ 14 3 0 14 3 0 3 1.90 31023 7.04 31023 3.37 0.00 Both
FAT2{1 2 1 0 2 1 0 2 6.30 31023 2.25 31022 0.128 0.00 2
IRF4{1 9 4 0 26 5 0 5 7.00 31023 2.41 31022 0.569 0.00 Both
FOXO1{ 8 4 0 10 4 0 4 7.60 3103 2.53 31022 4.02 0.00 2
STAT3 9 0 0 9 0 0 4 2.19 31022 6.08 31022 2 2 Both
RAPGEF1 8 3 0 10 3 0 3 2.98 31022 7.45 31022 2 2 WT
ABCA7 12 3 0 15 3 0 2 7.76 31022 1.67 31021 2 2 WT
RNF213 10 8 0 10 8 0 2 7.87 31022 1.67 31021 2 2 2
MUC16 17 12 0 39 25 0 2 8.32 31022 1.73 31021 2 2 2
HDAC7 8 4 0 8 4 0 2 8.94 31022 1.82 31021 2 2 WT
PRKDC 7 3 0 7 4 0 2 1.06 31021 2.05 31021 2 2 2
SAMD9 9 2 0 9 2 0 2 1.79 31021 3.01 31021 2 2 2
TAF1 10 0 0 10 0 0 2 3.03 31021 4.74 31021 2 2 2
PIM1 20 19 0 33 34 0 11 3.40 31021 5.23 31021 2 2 WT
COL4A2 8 2 0 8 2 0 2 7.64 31021 8.99 31021 2 2 2
EP300 8 7 1 8 7 1 3 9.54 31021 1.00 2 2 WT
Individual cases with non-synonymous (NS), synonymous (S) and truncating (T) mutations and the total number of mutations of each class are shown separately because some genes contained multiple
mutations in the same case. The P values indicated in bold are the upper limit on the P value for that gene determined with the approach described in ref. 19 (see Supplementary Methods), q is the Benjamini-
corrected q value, and NS SP and T SP refer to selective pressure estimates from this model for the acquisition of non-synonymous or truncatingmutations, respectively. Genes with a superscript of either A or G
were found to have mutations significantly enriched in ABC or GCB cases, respectively (P,0.05, Fisher’s exact test).
*Additional somatic mutations identified in larger cohorts and insertion/deletion mutations are not included in this total.
{ ‘Both’ indicates that we observed separate cases in which skewed expression was seen but where this skew was not consistent for the mutant or wild-type allele.
{Genessignificant at a false discovery rate of 0.03. SNVs inBCL2andpreviously confirmedhot spotmutations inEZH2andCD79Bareprobably somatic in these samples basedonpublishedobservations of others.
1Selective pressure estimates are both,1 indicating purifying selection rather than positive selection acting on this gene.
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chromosome (BAC) clone sequencing in eight FL cases to show that in
all eight cases themutations were in trans, affecting bothMLL2 alleles.
This observation is consistent with the notion that there is a complete,
or near-complete, loss ofMLL2 in the tumour cells of such patients.
With the exception of two primary FL cases and two DLBCL cell
lines (Pfeiffer and SU-DHL-9), themajority ofMLL2mutations seemed
to be heterozygous. Analysis of Affymetrix 500k SNP array data from
two FL cases with apparent homozygous mutations revealed that both
tumours showed copy number neutral loss of heterozygosity (LOH)
for the region of chromosome 12 containing MLL2 (Supplementary
Methods). Thus, in addition to bi-allelic mutation, LOH is a second,
albeit less common mechanism by whichMLL2 function is lost.
MLL2 was the most frequently mutated gene in FL, and among the
most frequently mutated genes in DLBCL (Fig. 2). We confirmed
MLL2 mutations in 31 of 35 FL patients (89%), in 12 of 37 DLBCL
patients (32%), in 10 of 17 DLBCL cell lines (59%) and in none of the
eight normal centroblast samples we sequenced. Our analysis pre-
dicted that the majority of the somatic mutations observed in MLL2
were inactivating (91% disrupted the reading frame or were truncat-
ing point mutations), indicating to us that MLL2 is a tumour sup-
pressor of significance in NHL.
Recurrent point mutations inMEF2B
Our selective pressure analysis also revealed genes with stronger pres-
sure for acquisition of amino acid substitutions than for nonsense
mutations. One such gene wasMEF2B, which had not previously been
linked to lymphoma. We found that 20 (15.7%) cases had MEF2B
cSNVs and 4 (3.1%) cases hadMEF2C cSNVs. All cSNVs detected by
RNA-seq affected either the MADS box or MEF2 domains. To deter-
mine the frequency and scope of MEF2B mutations, we Sanger-
sequenced exons 2 and 3 in 261 primary FL samples; 259 DLBCL
primary tumours; 17 cell lines; 35 cases of assorted NHL (IBL,
composite FL and PBMCL); and eight non-malignant centroblast
samples. We also used a capture strategy (Supplementary Methods)
to sequence the entire MEF2B coding region in the 261 FL samples,
revealing six additional variants outside exons 2 and 3. We thus iden-
tified 69 cases (34 DLBCL, 12.67%; and 35 FL, 15.33%) with MEF2B
cSNVs or indels, failing to observe novel variants in other NHL and
non-malignant samples. Of the variants 55 (80%) affected residues
within the MADS box and MEF2 domains encoded by exons 2 and 3
(Supplementary Table 11; Fig. 3b). Each patient generally had a single
MEF2B variant and we observed relatively few (eight in total, 10.7%)
truncation-inducing SNVs or indels. Non-synonymous SNVswere by
far themost common type of change observed, with 59.4% of detected
variants affecting K4, Y69, N81 or D83. In 12 casesMEF2Bmutations
were shown to be somatic, including representative mutations at each
of K4, Y69, N81 and D83 (Supplementary Table 12). We did not
detect mutations in ABC cases, indicating that somatic mutations in
MEF2B have a role unique to the development of GCBDLBCL and FL
(Fig. 2).
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Figure 2 | Overview of mutations and potential cooperative interactions in
NHL. This heat map displays possible trends towards co-occurrence (red) and
mutual exclusion (blue) of somatic mutations and structural rearrangements.
Colours were assigned by taking the minimum value of a left- and right-tailed
Fisher’s exact test. To capture trends a P-value threshold of 0.3 was used, with
the darkest shade of the colour indicating those meeting statistical significance
(P# 0.05). The relative frequency of mutations in ABC (blue), GCB (red),
unclassifiable (black)DLBCLs and FL (yellow) cases is shown on the left. Genes
were arranged with those having significant (P, 0.05, Fisher’s exact test)
enrichment for mutations in ABC cases (blue triangle) towards the top (and
left) and those with significant enrichment for mutations in GCB cases (red
triangle) towards the bottom (and right). The total number of cases in which
each gene contained either cSNVs or confirmed somatic mutations is shown at
the top. The cluster of blue squares (upper-right) results from the mutual
exclusion of the ABC-enrichedmutations (for example,MYD88, CD79B) from
the GCB-enriched mutations (for example, EZH2, GNA13). Presence of
structural rearrangements involving the two oncogenes BCL6 and BCL2
(indicated as BCL6s and BCL2s) was determined with FISH techniques using
break-apart probes (Supplementary Methods).
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Figure 3 | Summary and effect of somatic mutations affecting MLL2 and
MEF2B. a, Re-sequencing theMLL2 locus in 89 samples revealed mainly
nonsense (red circles) and frameshift-inducing indel mutations (orange
triangles; inverted triangles for insertions and upright triangles for deletions). A
smaller number of non-synonymous somatic mutations (green circles) and
point mutations or deletions affecting splice sites (yellow stars) were also
observed. All of the non-synonymous pointmutations affected a residue within
either the catalytic SET domain, the FYRC domain (FY-rich carboxy-terminal
domain) or PHD zinc finger domains. The effect of these splice-site mutations
onMLL2 splicing was also explored (Supplementary Figure 7). b, The cSNVs
and somatic mutations found inMEF2B in all FL and DLBCL cases sequenced
are shownwith the same symbols. Only the amino acids with variants in at least
two patients are labelled. cSNVs were most prevalent in the first two protein-
coding exons ofMEF2B (exons 2 and 3). The crystal structure of MEF2 bound
to EP300 supports the idea that two of the mutated sites (L67 and Y69) are
important in the interaction between these proteins (Supplementary Figure 8
and Supplementary Discussion)50.
Table 2 | Summary of types ofMLL2 somatic mutations
Sample Type FL DLBCL DLBCL cell-line Centroblast
Truncation 18 4 7 0
Indel with frameshift 22 8 6 0
Splice site 4 2 0 0
SNV 3 2 2 0
Any mutation/
number of cases 31/35 12/37 10/17 0/8
Percentage 89 32 59 0
ARTICLE RESEARCH
1 8 A U G U S T 2 0 1 1 | V O L 4 7 6 | N A T U R E | 3 0 1
Macmillan Publishers Limited. All rights reserved©2011
Discussion
In our study of genome, transcriptome and exome sequences from
127 B-cell NHL cases, we identified 109 genes with clear evidence of
somatic mutation in multiple individuals. Significant selection seems
to act on at least 26 of these for the acquisition of either nonsense or
missense mutations. To the best of our knowledge, the majority of
these genes had not previously been associated with any cancer type.
We observed an enrichment of somatic mutations affecting genes
involved in transcriptional regulation and, more specifically, chro-
matin modification.
MLL2 emerged from our analysis as a major tumour suppressor
locus in NHL. It is one of six human H3K4-specific methyltrans-
ferases29, all of which share homology with the Drosophila trithorax
gene. Trimethylated H3K4 (H3K4me3) is an epigenetic mark assoc-
iated with the promoters of actively transcribed genes. By laying down
this mark, MLLs are responsible for the transcriptional regulation of
developmental genes including the homeobox (Hox) gene family30
which collectively control segment specificity and cell fate in the
developing embryo31,32. EachMLL family member is thought to target
different subsets of Hox genes33 and in addition, MLL2 is known to
regulate the transcription of a diverse set of genes34. Recently, MLL2
mutations were reported in a small-cell lung cancer cell line35 and in
renal carcinoma36, but the frequency of nonsense mutations affecting
MLL2 in these cancers was not established in these reports.
Inactivating mutations were reported recently in MLL2 or MLL3 in
16% of medulloblastoma patients37, further implicating MLL2 as a
cancer gene.
Our data link MLL2 somatic mutations to B-cell NHL. The
reported mutations are likely to be inactivating and in eight of the
cases with multiple mutations, we confirmed that both alleles were
affected, presumably resulting in essentially complete loss of MLL2
function. The high prevalence ofMLL2mutations in FL (89%) equals
the frequency of the t(14;18)(q32;q21) translocation, which is con-
sidered the most prevalent genetic abnormality in FL3. In DLBCL
tumour samples and cell lines, MLL2 mutation frequencies were
32% and 59%, respectively, also exceeding the prevalence of the most
frequent cytogenetic abnormalities, such as the various translocations
involving 3q27, which occur in 25–30% of DLBCLs and are enriched
in ABC cases38. Importantly, we foundMLL2mutated in both DLBCL
subtypes (Fig. 2). Our analyses thus indicate that MLL2 acts as a
central tumour suppressor in FL and both DLBCL subtypes.
The MEF2 gene family encodes four related transcription factors
that recruit histone-modifying enzymes including histone deacetylases
(HDACs) and HATs in a calcium-regulated manner. Although trun-
cating variants were detected in our analysis of MEF2 gene family
members, our analysis suggests that, in contrast toMLL2,MEF2 family
members tend to selectively acquire non-synonymous amino acid sub-
stitutions. In the case ofMEF2B, 59.4% of all the cSNVs were found at
four sites within the protein (K4, Y69, N81 and D83), and all four of
these sites were confirmed to be targets of somatic mutation. D83 is
affected in 39% of theMEF2B alterations, resulting in replacement of
the charged aspartate with any of alanine, glycine or valine. Although
we cannot yet predict the consequences of these substitutions on
protein function, it seems likely that their effect would have an impact
on the ability of MEF2B to facilitate gene expression and thus have a
role in promoting the malignant transformation of germinal centre B
cells to lymphoma (Supplementary Discussion).
MEF2Bmutations can be linked to CREBBP and EP300mutations,
and to recurrent Y641 mutations in EZH2 (ref. 13). One target of
CREBBP/EP300 HAT activity is H3K27, which is methylated by
EZH2 to repress transcription. There is evidence that the action of
EZH2 antagonizes that of CREBBP/EP300 (ref. 39). One function of
MEF2 is to recruit either HDACs or CREBBP/EP300 to target genes40,
and it has been suggested that HDACs compete with CREBBP/EP300
for the same binding site on MEF2 (ref. 41). Under normal Ca21
levels, MEF2 is bound by type IIa HDACs, which maintain the tails
of histone proteins in a deacetylated repressive chromatin state42.
Increased cytoplasmic Ca21 levels induce the nuclear export of
HDACs, enabling the recruitment of HATs such as CREBBP/
EP300, facilitating transcription at MEF2 target genes. Mutation of
CREBBP, EP300 orMEF2Bmay have an impact on the expression of
MEF2 target genes owing to reduced acetylation of nucleosomes near
these genes (Supplementary Figure 5; Supplementary Discussion). In
light of the recent finding that heterozygous EZH2 Y641 mutations
enhance overall H3K27 trimethylation activity of PRC2 (refs 43, 44),
it is possible that mutation of bothMLL2 and EZH2 could cooperate
in reducing the expression of some of the same target genes. Our data
indicate that (1) post-transcriptionalmodification of histones is of key
importance in germinal centre B cells and (2) deregulated histone
modification due to these mutations is likely to result in reduced
acetylation and enhanced methylation, and acts as a core driver event
in the development of NHL (Supplementary Figure 5).
METHODS SUMMARY
All samples analysed contained at least 50% tumour cells. Genomes, exomes and
transcriptomes were sequenced using a combination of Illumina GAIIx and
HiSeq 2000 instruments to read lengths of between 36 and 100 nucleotides.
Exome capture was performed using the Agilent SureSelect Target Enrichment
System Protocol (Version 1.0, September 2009). Alignment was accomplished
using BWA45 and variants were identified using SNVmix46. Variants were manu-
ally reviewed in IGV and were confirmed (where applicable) by PCR followed by
either Sanger sequencing or Illumina re-sequencing. Structural rearrangements
in genomes and transcriptomes were identified using ABySS47. Gene expression
values used for subtype assignment were calculated as reads per kilobase gene
model per million mapped reads (RPKM) values48 and subtypes were assigned
using an adaptation of themethod developed for data fromAffymetrix expression
arrays49 trained with samples previously classified by this standard approach.
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